Exact Sciences' Cologuard preferred in updated ACS guideline
The guideline also added blood tests for people unwilling or unable to complete preferred screening.
See the latest news and media coverage for Exact Sciences. We track all announcements, press releases, and industry mentions in real time, all in one place.
Cancer screening and diagnostic test company
exactsciences.comLast updated
In short: Exact Sciences was acquired by Abbott for $23 billion and raised its 2025 revenue guidance following record results and new product launches.
The guideline also added blood tests for people unwilling or unable to complete preferred screening.
Revenue grew 18% to $3.25B, with Screening and Precision Oncology both strong.
The milestone underscores its role as a global standard-of-care, helping an estimated 1.6 million patients avoid potentially unnecessary chemotherapy.
The law establishes a Medicare coverage pathway for multi-cancer early detection tests, potentially expanding access to Cancerguard for millions.
Abbott cut its annual profit forecast on Thursday due to an impact from its $23 billion acquisition of cancer test maker Exact Sciences, sending its...
Shares of the cancer diagnostics company Exact Sciences surged 25% late Wednesday, after a report said the conglomerate Abbott Laboratories is close to a deal...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or...
Bloomer announced, "We are raising total full year revenue to between $3.22 billion and $3.235 billion, an increase of $78 million at midpoint. This includes...
Track Exact Sciences and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Exact Sciences and other trending companies.